Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice

British Journal of Cancer

Volumn 75, Issue 5, 1997, Pages 656-659

  Morelli, D ^a   Menard S ^a   Cazzaniga, S ^a   Colnaghi, M I ^a   Balsari, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anthracycline; Antidotal activity; Monoclonal antibody; Myelosuppression

Indexed keywords

DOXORUBICIN; DRUG ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA P 388; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIBIA; TOPICAL DRUG ADMINISTRATION;

EID: 0031040391     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.117     Document Type: Article

References (27)

1. Anilkumar TV, Sarraf CE, Hunt T and Alison MR (1992) The nature of cytotoxic drug - induced cell death in murine intestinal crypts. Br J Cancer 65: 552-558
2. Balsari A, Morelli D, Ménard S, Tagliabue E, Colnaghi MI and Ghione M (1990) A new monoclonal antibody recognizing anthracyclinic molecule. Anticancer Res 10: 129-132
3. Balsari A, Ménard S. Colnaghi MI and Ghione M (1991) Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. Int J Cancer 47: 889-892
4. Balsari AI., Morelli D, Ménard S, Veronesi U and Colnaghi MI (1994) Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 8: 226-230
5. Barry MA, Behnke CA and Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362
6. Berlin Ö, Samid D, Donthineni-Rao R, Akeson W, Amiel D and Woods VL (1993) Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 53: 4890-4895
7. Chahner BA and Myers CE (1993) Antitumor antibiotics. In Cancer Principles and Practice of Oncology, De Vita VT, Hellman S and Sosenberg SA (eds), pp. 374-384, Lippincott: Philadelphia.
8. Chesson BD, Lacerna L, Leyland-Jones B and Sarosy G RE (1989) Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med 110: 51-65
9. Dexter TM (1989) Regulation of hemopoietic cell growth and development: experimental and clinical studies. Leukemia 3: 469-474
10. Eaves CJ, Cashman JD, Kay RJ, Dougherty GJ, Otsuka T, Gaboury LA, Hogge DE, Lansdorp PM, Eaves AC and Humphries RK (1991) Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 78: 110-117
11. Grzegorzewski K, Ruscetti FW, Usui N, Damia G, Longo DL, Carlino JA, Keller JR and Wiltrout RH (1994) Recombinant transforming growth factor betal and beta2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180: 1047-1057
12. Guigon M, Lemoine F and Najman A (1994) Bone marrow protection. Bone Marrow Transplant 13: 93-95
13. Gulati SC, Yahalom J and Portlock C (1991) Autologous bone marrow transplantation. Curr Probl Cancer 15: 1-35
14. Hénon PR (1993) Peripheral blood stem cell transplantations: past present and future. Stem Cells 11: 154-172
15. Hénon P, Liang H, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E and Kandel G (1992) Comparison of hematopoietic and immune recovery alter autologous bone marrow or blood stem cell transplant. Bone Marrow Transplant 9: 285-291
16. Harnung RL and Longo DL (1992) Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high dose cyclophosphamide therapy. Blood 80: 77-83
17. Lieschke GJ and Burgess AW (1992) Granulocyte stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327: 28-35
18. Mazué G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podesta A, Della Torre P and Moneta D (1995) Anthracyclines: a review of general and special toxicity studies. Int J Oncol 7: 713-726
19. Metcalf D (1990) The colony stimulating factors discover, development and clinical applications. Cancer 65: 2185-2195
20. Moore MAS (1992) Does stem cell exhaustion result from combining hematopoietic growth factros with chemotherapy? It so, how do we prevent it. Blood 80: 3-7
21. Morelli D, Ménard S, Colnaghi MI and Balsari A (1996) Oral administration of antidoxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res 56: 2082-2085
22. Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQK, Dart GW, Horvath N, Davy MLJ, Olweny CLM, Abdi E and Juttner CA (1992) Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants. Bone Marrow Transplant 9: 277-284
23. Sardini A, Villa E, Morelli D, Ghione M, Ménard S, Colnaghi MI and Balsari A (1992) An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. Int J Cancer 50: 617-620
24. Schofield R (1986) Assessment of cytotoxic injury to bone marrow. Br J Cancer 53: 115-125
25. Tubiana M, Carde P and Friendel E (1993) Ways of minimising hematopoietic damage induced by radiation and cytostatic drugs - the possible role of inhibitors. Radiother Oncol 29: 1-17
26. Vassort F, Frindel E and Tubiana M (1971) Effects of hydroxyurea on the kinetics of colony forming units of bone marrow in the mouse. Cell Tissue Kinet 4: 423-431
27. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670-686